Animal Models and Retroviral Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Expert Rev Vaccines. 2010 Sep;9(9):997-1005. doi: 10.1586/erv.10.104.
The large human efficacy trail in Thailand, RV144, was concluded in the summer of 2009. This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition. This trial represents the first sign that a preventive vaccine for HIV may be feasible. The vaccine regimen tested in Thailand consisted of priming with a Canarypox vector carrying three synthetic HIV genes. The priming was followed by booster inoculations with two recombinant envelope proteins from HIV, clade B and E. The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination, has brought together many researchers with the common goal of improving the development of a safe and effective vaccine for HIV.
泰国开展的大型人类功效试验 RV144 于 2009 年夏得出结论。这是首个表明在预防 HIV 感染方面具有一定但显著效果的 III 期试验。该试验标志着预防 HIV 的疫苗可能成为现实。在泰国进行的疫苗试验方案包括使用携带三种合成 HIV 基因的金丝雀痘载体进行初级免疫，随后用两种来自 HIV clade B 和 E 的重组包膜蛋白进行加强免疫。为了解该疫苗组合诱导的新反应在预防 HIV 感染方面的作用，许多研究人员齐聚一堂，共同目标是研发出安全有效的 HIV 疫苗。
